Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research. 
 The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
| Name | Price | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCAM1 Antibody (Ascites) | Login | NCAM1 Antibody (Ascites) | ||||||||||||||||
| 
 | ||||||||||||||||||
| NR3C1 Antibody | Login | NR3C1 Antibody | ||||||||||||||||
| 
 | ||||||||||||||||||
| NR3C1 Antibody | Login | NR3C1 Antibody | ||||||||||||||||
| 
 | ||||||||||||||||||
| RAD51 Antibody | Login | RAD51 Antibody | ||||||||||||||||
| 
 | ||||||||||||||||||
| RAD51 Antibody | Login | RAD51 Antibody | ||||||||||||||||
| 
 | ||||||||||||||||||
| FGF4 Antibody | Login | FGF4 Antibody | ||||||||||||||||
| 
 | ||||||||||||||||||
| FGF4 Antibody | Login | FGF4 Antibody | ||||||||||||||||
| 
 | ||||||||||||||||||
| KEAP1 Antibody (C-term) | Login | KEAP1 Antibody (C-term) | ||||||||||||||||
| 
 | ||||||||||||||||||
| SMAD3 Antibody (S213) | Login | SMAD3 Antibody (S213) | ||||||||||||||||
| 
 | ||||||||||||||||||
| SMAD3 Antibody (S213) | Login | SMAD3 Antibody (S213) | ||||||||||||||||
| 
 | ||||||||||||||||||
| Anti-EphrinB (Tyr298) Antibody | Login | Anti-EphrinB (Tyr298) Antibody | ||||||||||||||||
| 
 | ||||||||||||||||||
| Anti-EphrinB (Tyr331) Antibody | Login | Anti-EphrinB (Tyr331) Antibody | ||||||||||||||||
| 
 | ||||||||||||||||||
| Anti-FANCI (Ser559) Antibody | Login | Anti-FANCI (Ser559) Antibody | ||||||||||||||||
| 
 | ||||||||||||||||||
| EGF Antibody (Center) | Login | EGF Antibody (Center) | ||||||||||||||||
| 
 | ||||||||||||||||||
| CD4 Antibody (C-term) | Login | CD4 Antibody (C-term) | ||||||||||||||||
| 
 | ||||||||||||||||||
| CD4 Antibody (C-term) | Login | CD4 Antibody (C-term) | ||||||||||||||||
| 
 | ||||||||||||||||||
| Anti-Microtubule Associated Protein 2 C/D (MAP2C/D) Antibody | Login | Anti-Microtubule Associated Protein 2 C/D (MAP2C/D) Antibody | ||||||||||||||||
| 
 | ||||||||||||||||||
| Anti-SOX2 Antibody | Login | Anti-SOX2 Antibody | ||||||||||||||||
| 
 | ||||||||||||||||||
| Anti-Vimentin Antibody | Login | Anti-Vimentin Antibody | ||||||||||||||||
| 
 | ||||||||||||||||||
| Anti-Vimentin Antibody | Login | Anti-Vimentin Antibody | ||||||||||||||||
| 
 | ||||||||||||||||||
| Anti-Vimentin Antibody | Login | Anti-Vimentin Antibody | ||||||||||||||||
| 
 | ||||||||||||||||||
| Anti-c-Abl (C-terminal region) Antibody | Login | Anti-c-Abl (C-terminal region) Antibody | ||||||||||||||||
| 
 | ||||||||||||||||||
| Anti-c-Abl (Tyr-245), Phosphospecific Antibody | Login | Anti-c-Abl (Tyr-245), Phosphospecific Antibody | ||||||||||||||||
| 
 | ||||||||||||||||||
| Anti-c-Abl (Tyr-412), Phosphospecific Antibody | Login | Anti-c-Abl (Tyr-412), Phosphospecific Antibody | ||||||||||||||||
| 
 | ||||||||||||||||||
| Anti-Actin (N-terminal region) Antibody | Login | Anti-Actin (N-terminal region) Antibody | ||||||||||||||||
| 
 | ||||||||||||||||||


 
                         
	 
 